WO2022165382A1 - Phenylethylidenehydrazine combination therapies - Google Patents
Phenylethylidenehydrazine combination therapies Download PDFInfo
- Publication number
- WO2022165382A1 WO2022165382A1 PCT/US2022/014629 US2022014629W WO2022165382A1 WO 2022165382 A1 WO2022165382 A1 WO 2022165382A1 US 2022014629 W US2022014629 W US 2022014629W WO 2022165382 A1 WO2022165382 A1 WO 2022165382A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antidepressant
- disorder
- peh
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- RUZSWLOEFLRSGJ-JXMROGBWSA-N phenylethylidenehydrazine Chemical compound N\N=C\CC1=CC=CC=C1 RUZSWLOEFLRSGJ-JXMROGBWSA-N 0.000 title claims abstract description 103
- 238000002648 combination therapy Methods 0.000 title description 4
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 150
- 229940005513 antidepressants Drugs 0.000 claims abstract description 147
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 145
- 238000000034 method Methods 0.000 claims abstract description 128
- 238000011282 treatment Methods 0.000 claims abstract description 68
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 53
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 37
- 230000036506 anxiety Effects 0.000 claims abstract description 20
- 208000012672 seasonal affective disease Diseases 0.000 claims abstract description 20
- 208000019906 panic disease Diseases 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 110
- 239000002552 dosage form Substances 0.000 claims description 49
- 239000003814 drug Substances 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 229940044601 receptor agonist Drugs 0.000 claims description 36
- 239000000018 receptor agonist Substances 0.000 claims description 36
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 25
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 25
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 22
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 20
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 20
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 20
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 19
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 18
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 229960002495 buspirone Drugs 0.000 claims description 10
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical group C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 10
- 239000006186 oral dosage form Substances 0.000 claims description 10
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 9
- 208000020925 Bipolar disease Diseases 0.000 claims description 8
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims description 8
- 229960002263 vortioxetine Drugs 0.000 claims description 8
- 229960001800 nefazodone Drugs 0.000 claims description 7
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 7
- 229960003991 trazodone Drugs 0.000 claims description 7
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- 206010012335 Dependence Diseases 0.000 claims description 5
- 239000002841 Lewis acid Substances 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 150000007517 lewis acids Chemical class 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 4
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 4
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- QYFHCFNBYQZGKW-BDQAORGHSA-N 8-[4-[[(3s)-5-methoxy-3,4-dihydro-2h-chromen-3-yl]-propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione;hydrochloride Chemical compound Cl.CCCN([C@H]1CC2=C(OC)C=CC=C2OC1)CCCCN(C(C1)=O)C(=O)CC21CCCC2 QYFHCFNBYQZGKW-BDQAORGHSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 4
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229940022663 acetate Drugs 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 229950000420 alnespirone Drugs 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960002519 amoxapine Drugs 0.000 claims description 4
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 4
- 229940072107 ascorbate Drugs 0.000 claims description 4
- 229940050390 benzoate Drugs 0.000 claims description 4
- 229940114081 cinnamate Drugs 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 4
- 229960005217 dapoxetine Drugs 0.000 claims description 4
- 229960003914 desipramine Drugs 0.000 claims description 4
- 229960001623 desvenlafaxine Drugs 0.000 claims description 4
- 239000001177 diphosphate Substances 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 4
- 235000011180 diphosphates Nutrition 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 4
- 229960005426 doxepin Drugs 0.000 claims description 4
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 4
- 229960002866 duloxetine Drugs 0.000 claims description 4
- 229960004341 escitalopram Drugs 0.000 claims description 4
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 4
- 229960002053 flibanserin Drugs 0.000 claims description 4
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002464 fluoxetine Drugs 0.000 claims description 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 4
- 229960004038 fluvoxamine Drugs 0.000 claims description 4
- 229940050411 fumarate Drugs 0.000 claims description 4
- 229960000647 gepirone Drugs 0.000 claims description 4
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940050410 gluconate Drugs 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 4
- 229960004801 imipramine Drugs 0.000 claims description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 4
- 229940001447 lactate Drugs 0.000 claims description 4
- 229940070765 laurate Drugs 0.000 claims description 4
- 229950001590 lesopitron Drugs 0.000 claims description 4
- AHCPKWJUALHOPH-UHFFFAOYSA-N lesopitron Chemical compound C1=C(Cl)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 AHCPKWJUALHOPH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000685 levomilnacipran Drugs 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 229940105132 myristate Drugs 0.000 claims description 4
- 229960001158 nortriptyline Drugs 0.000 claims description 4
- 229960002296 paroxetine Drugs 0.000 claims description 4
- 150000007965 phenolic acids Chemical class 0.000 claims description 4
- 229960002601 protriptyline Drugs 0.000 claims description 4
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 4
- 229950009693 repinotan Drugs 0.000 claims description 4
- YGYBFMRFXNDIPO-QGZVFWFLSA-N repinotan Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 YGYBFMRFXNDIPO-QGZVFWFLSA-N 0.000 claims description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
- 229960002073 sertraline Drugs 0.000 claims description 4
- 229940075554 sorbate Drugs 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
- 229960002431 trimipramine Drugs 0.000 claims description 4
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004688 venlafaxine Drugs 0.000 claims description 4
- 208000012239 Developmental disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 230000003542 behavioural effect Effects 0.000 claims description 3
- 229960001058 bupropion Drugs 0.000 claims description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 229960001785 mirtazapine Drugs 0.000 claims description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003089 pramipexole Drugs 0.000 claims description 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 3
- 239000007848 Bronsted acid Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 abstract description 14
- 229940002612 prodrug Drugs 0.000 abstract description 14
- 238000011284 combination treatment Methods 0.000 abstract description 3
- 230000000670 limiting effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229960000964 phenelzine Drugs 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000011200 topical administration Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000969 carrier Substances 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 7
- -1 carrier Substances 0.000 description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 229960003732 tyramine Drugs 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 description 2
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 2
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229960000450 esketamine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 206010050013 Abulia Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000002698 neuron blocking agent Substances 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000014483 powder concentrate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Definitions
- Anxiety disorders such as generalized anxiety disorder (GAD), seasonal affective disorder (SAD), depression, and panic disorder are the most common mental health concern in the United States today. See, e.g., Bystritsky, A. (2006) Molecular Psychiatry 11(9): 805- 814; Buigues and Vallego (1987) The Journal of Clinical Psychiatry 48(2): 55-59; Blanco et al. (2003) Depression and Anxiety 18(1): 29-40. Over 19% of adults in the United States have an anxiety disorder, and approximately 7% of children aged 3-17 experience issues with anxiety each year. Most people develop symptoms before age 21.
- Anxiety disorders are a group of related conditions with unique symptoms; however, all anxiety disorders have one thing in common: persistent, excessive fear or worry in situations that are not threatening.
- individuals experience one or more of the following symptoms: feelings of apprehension or dread, feeling tense or jumpy, restlessness or irritability, anticipating the worst and being watchful for signs of danger, pounding or racing heart and shortness of breath, sweating, tremors, twitches, headaches, fatigue, insomnia, upset stomach, frequent urination, and diarrhea.
- Depression is among the most disabling of all medical disorders, with a lifetime prevalence of approximately 17%. It frequently appears early in life, can run a chronic course, and can adversely affect the prognosis of other medical illnesses, such as coronary vascular disease, diabetes, and osteoporosis. Depression is characterized by a depressed mood, and markedly diminished interest or pleasure in activities. Other symptoms include significant weight loss or weight gain, decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to think or concentrate or indecisiveness, recurrent thoughts of death, and suicidal ideation or suicidal attempts. Depression can vary in severity from mild to very severe.
- SSRIs serotonin specific reuptake inhibitors
- SNRIs serotonin noradrenergic reuptake inhibitors
- NDRIs norepinephrinedopamine reuptake inhibitors
- MAOIs mono-amine oxidase inhibitors
- TCAs tricyclic antidepressants
- anti-psychotics “natural products” (e.g, Kava-Kava, St. John's Wort), dietary supplement (e.g, s-adenosylmethionine), and others.
- TMS Transcranial Magnetic Stimulation
- ECT Electroconvulsive Therapy
- ketamine has been used as an anti-depressant treatment.
- the FDA approved esketamine treatment has a rapid response that is particularly useful for acutely suicidal patients, although clinical trials of esketamine have shown a minimal improvement in depression rating scales compared to placebo.
- compositions and methods for treating psychological disorders such as severe anxiety disorders, and, in particular, for treating generalized anxiety disorder, panic disorder, seasonal affective disorder, and treatmentresistant depression.
- the invention in one aspect, relates to methods for treating psychological disorders such as, for example, severe anxiety disorders (e.g., generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety) and obsessive-compulsive disorder (OCD) using phenylethylidenehydrazine (PEH) or a pharmaceutically acceptable salt or prodrug thereof, a GABA transaminase enzyme inhibitor, in combination with an antidepressant, compositions comprising PEH or a salt or prodrug thereof and an antidepressant, and methods of making and using same.
- severe anxiety disorders e.g., generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety
- OCD obsessive-compulsive disorder
- PH phenylethylidenehydrazine
- phenylethylidenehydrazine PEG
- an antidepressant an effective amount of phenylethylidenehydrazine (PEH) or a pharmaceutically acceptable salt thereof, and an antidepressant.
- compositions comprising PEH or a pharmaceutically acceptable salt thereof, an antidepressant, and a pharmaceutically acceptable carrier, wherein at least one of PEH or the pharmaceutically acceptable salt thereof and the antidepressant is present in a therapeutically effective amount, or wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are together present in a therapeutically effective amount.
- compositions comprising PEH or a pharmaceutically acceptable salt thereof, a 5HTIA receptor agonist, and a pharmaceutically acceptable carrier, wherein at least one of PEH or the pharmaceutically acceptable salt thereof and the 5HTIA receptor agonist is present in a therapeutically effective amount, or wherein PEH or the pharmaceutically acceptable salt thereof and the 5HTIA receptor agonist are together present in a therapeutically effective amount.
- kits comprising PEH or a pharmaceutically acceptable salt thereof, and an antidepressant, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
- kits comprising PEH or a pharmaceutically acceptable salt thereof, and a 5HTIA receptor agonist, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
- FIG. 1 shows representative data illustrating the average systolic blood pressure (SBP) increase observed when taking a variety of drugs with 40 mg of tyramine taken with a meal.
- SBP systolic blood pressure
- FIG. 2 shows representative data illustrating that a postural drop in SBP is highly correlated with TCP plasma concentration.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
- the terms “about” and “at or about” mean that the amount or value in question can be the value designated some other value approximately or about the same. It is generally understood, as used herein, that it is the nominal value indicated ⁇ 10% variation unless otherwise indicated or inferred. The term is intended to convey that similar values promote equivalent results or effects recited in the claims. That is, it is understood that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but can be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art.
- an amount, size, formulation, parameter or other quantity or characteristic is “about” or “approximate” whether or not expressly stated to be such. It is understood that where “about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
- references in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed.
- X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
- a weight percent (wt. %) of a component is based on the total weight of the formulation or composition in which the component is included.
- the term “subject” can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian.
- the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent.
- the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
- the subject is a mammal.
- a patient refers to a subject afflicted with a disease or disorder.
- patient includes human and veterinary subjects.
- treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
- this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- the term covers any treatment of a subject, including a mammal (e.g, a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease.
- the subject is a mammal such as a primate, and, in a further aspect, the subject is a human.
- subject also includes domesticated animals (e.g, cats, dogs, etc.), livestock (e.g, cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g, mouse, rabbit, rat, guinea pig, fruit fly, etc.).
- domesticated animals e.g, cats, dogs, etc.
- livestock e.g, cattle, horses, pigs, sheep, goats, etc.
- laboratory animals e.g, mouse, rabbit, rat, guinea pig, fruit fly, etc.
- the term “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed.
- the term “diagnosed” means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the compounds, compositions, or methods disclosed herein.
- administering refers to any method of providing a pharmaceutical preparation to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent.
- a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition.
- a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
- the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition.
- a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration.
- compositions can contain such amounts or submultiples thereof to make up the daily dose.
- the dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
- a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
- dosage form means a pharmacologically active material in a medium, carrier, vehicle, or device suitable for administration to a subject.
- a dosage form can comprise a disclosed compound, a product of a disclosed method of making, or a salt, solvate, or polymorph thereof, in combination with a pharmaceutically acceptable excipient, such as a preservative, buffer, saline, or phosphate buffered saline.
- Dosage forms can be made using conventional pharmaceutical manufacturing and compounding techniques.
- Dosage forms can comprise inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants (e.g., ascorbic acid, alpha-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene9-10 nonyl phenol, sodium desoxycholate), solution and/or cryo/lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic adjustment agents (e.g., salts or sugars), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsilozone), preservatives (e.g., thimerosal, 2-
- kit means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
- instruction(s) means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents, and are meant to include future updates.
- therapeutic agent include any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to an organism (human or nonhuman animal), induces a desired pharmacologic, immunogenic, and/or physiologic effect by local and/or systemic action.
- the term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs and the like.
- therapeutic agents include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
- the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti-inflammatory agents, anti-epileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants, anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiadrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics; antispasmodics, cardiovascular preparations (including calcium channel blockers, beta-blockers, an
- the agent may be a biologically active agent used in medical, including veterinary, applications and in agriculture, such as with plants, as well as other areas.
- therapeutic agent also includes without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; or substances which affect the structure or function of the body; or pro- drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.
- pharmaceutically acceptable describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.
- derivative refers to a compound having a structure derived from the structure of a parent compound (e.g, PEH) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds.
- exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound.
- the term “pharmaceutically acceptable carrier” refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
- Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
- Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use.
- Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
- Phenelzine is a potent irreversible, non-selective monoamine oxidase inhibitor (MAOI). It is used clinically for the treatment of a number of psychiatric disorders, including major depression (McGrath, et al. 1986), atypical depression (Paykel, et al. 1982), and social anxiety disorder (Liebowitz, et al. 1988).
- PLZ is also an inhibitor of y-aminobutyric acid (GABA) and alanine (ALA), presumably due to its inhibition of GABA transaminase and ALA transaminase, respectively ((Popov and Matthies (1969) J Neurochem 16(3): 899-907; Paslawski, et al. (1995) Prog Brain Res 106: 181-186).
- GABA y-aminobutyric acid
- ALA alanine
- MAO monoamine oxidase
- the disclosed prodrugs would be present with a counterion.
- exemplary counterions are well-known by those of ordinary skill in the art, and include, but are not limited to, halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid.
- a PLZ prodrug and a PEH prodrug can be present as follows:
- X is a counterion, such as, for example, halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sul
- PEH and PLZ share many pharmacological properties, an important distinction is that PEH is only a weak and transient inhibitor of MAO-A and MAO-B (Paslawski, et al. (2001) Drug Dev Res 54: 35-39; MacKenzie, et al. (2008) BioorgMed Chem 16(17): 8254-8263).
- a major drawback to clinical use of PLZ is a potential interaction with tyramine-containing foods such as aged cheeses and meats, overripe fruits and vegetables, and fermented beverages.
- PLZ By irreversibly inhibiting MAO-A in the gut, PLZ prevents the metabolism of dietary tyramine, a sympathomimetic agent, which can then enter the bloodstream and cause unpleasant symptoms ranging from headache to hypertensive crisis. Notably, because PEH is a poor inhibitor of MAO-A, it should not be associated with this adverse effect.
- PEH or a pharmaceutically acceptable salt or prodrug thereof and an antidepressant such as, for example, a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or a 5HTIA receptor agonist
- an antidepressant such as, for example, a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or a 5HTIA receptor agonist
- SSRI selective serotonin reuptake inhibitor
- SNRI serotonin-norepinephrine reuptake inhibitor
- TCA tricyclic antidepressant
- 5HTIA receptor agonist e.g. a selective serotonin reuptake inhibitor
- SNRI serotonin-norepin
- a psychological disorder in a subject in need thereof comprising administering to the subject an effective amount of PEH or a pharmaceutically acceptable salt thereof, and an antidepressant.
- the pharmaceutically acceptable salt is a compound having a structure: wherein X is a counterion.
- Exemplary counterions include, but are not limited to, halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid.
- the pharmaceutically acceptable salt is a Lewis acid-base adduct.
- the Lewis acid-base adduct is a compound having a structure represented by a formula: wherein X’ is a residue of a Lewis acid such as, for example, a non-Bronsted acid.
- residues of Lewis acids include, but are not limited to, -BF3 and -A1CL.
- disclosed are methods for treating a psychological disorder in a subject comprising administering to the subject an effect amount of a compound having a structure: and an antidepressant.
- methods for treating a psychological disorder in a subject comprising administering to the subject an effective amount of the compound and a 5HTIA receptor agonist.
- disclosed are methods for treating a psychological disorder in a subject comprising administering to the subject an effective amount of PEH and an antidepressant.
- methods for treating a psychological disorder in a subject comprising administering to the subject an effective amount of PEH and a 5HTIA receptor agonist.
- disclosed are methods for treating treatment-resistant depression in a human subject comprising orally administering to the subject an effective amount of a compound having a structure: and an antidepressant, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
- methods for treating treatment-resistant depression in a human subject comprising orally administering to the subject an effective amount of the compound and a 5HTIA receptor agonist, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
- disclosed are methods for treating treatment-resistant depression in a human subject comprising orally administering to the subject an effective amount of PEH and an antidepressant, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
- methods for treating treatment-resistant depression in a human subject comprising orally administering to the subject an effective amount of PEH and a 5HTIA receptor agonist, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
- the method comprises administering a pharmaceutical composition comprising an effective amount of the compound. In a further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of the compound and the antidepressant. In a still further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of the compound and a 5HTIA receptor agonist.
- the method comprises administering a pharmaceutical composition comprising an effective amount of PEH. In a further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of PEH and the antidepressant. In a still further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of PEH and a 5HTIA receptor agonist.
- the method comprises administering a single dose of the compound. In a further aspect, the method comprises administering multiple doses of the compound.
- the method comprises administering a single dose of PEH. In a further aspect, the method comprises administering multiple doses of PEH.
- a single administration of the compound is sufficient to alleviate symptoms of the psychological disorder for a period of at least 4 hours, at least 6 hours, at least 8 hours, or at least 10 hours.
- a single administration of PEH is sufficient to alleviate symptoms of the psychological disorder for a period of at least 4 hours, at least 6 hours, at least 8 hours, or at least 10 hours.
- the compound and the antidepressant are administered sequentially. In a further aspect, the compound is administered prior to administration of the antidepressant. In a still further aspect, the compound is administered subsequent to administration of the antidepressant. [0062] In some aspects, PEH and the antidepressant are administered sequentially. In a further aspect, PEH is administered prior to administration of the antidepressant. In a still further aspect, PEH is administered subsequent to administration of the antidepressant.
- the compound and the antidepressant are administered simultaneously.
- PEH and the antidepressant are administered simultaneously.
- the compounds and pharmaceutical compositions comprising the compounds are administered to a subject in need thereof.
- the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
- the subject is preferably a mammal, such as a human.
- the subject Prior to administering the compounds or compositions, the subject can be diagnosed with a need for treatment of a psychiatric disorder, such as depression.
- the subject is a mammal.
- the mammal is a human.
- the subject has been diagnosed as having the psychological disorder prior to the administering step.
- the subject has not been diagnosed as having a seizure disorder, a developmental disorder, a neurological disorder, a behavioral disorder, or addiction prior to the administering step.
- the subject has not been diagnosed as having a disorder associated with depression (i.e., a disorder that is a comorbidity with depression) such as, for example, addiction, a substance use disorder (e.g., alcohol use disorder, nicotine use disorder), a personality disorder (e.g, borderline personality disorder), post-traumatic stress disorder, and obsessive-compulsive disorder.
- the method further comprises identifying a subject in need of treatment of a psychological disorder.
- the compounds or compositions can be administered to the subject according to any method.
- Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration.
- Administration can be continuous or intermittent.
- a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition.
- a preparation can also be administered prophylactically; that is, administered for prevention of an infection or condition, such as a psychiatric disorder.
- the compound and the antidepressant are together present in an effective amount.
- the compound and the antidepressant are each present in individually effective amounts.
- the compound is present in an individually effective amount.
- the antidepressant is present in an individually effective amount.
- PEH and the antidepressant are together present in an effective amount.
- PEH and the antidepressant are each present in individually effective amounts.
- PEH is present in an individually effective amount.
- the antidepressant is present in an individually effective amount.
- the effective amount is a prophylactically effective amount. In a further aspect, the effective amount is a therapeutically effective amount.
- the therapeutically effective amount or dosage of the compound can vary within wide limits. Such a dosage is adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as well as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70 Kg or more, a daily dosage of about 10 mg to about 1000 mg, preferably from about 20 mg to about 800 mg, should be appropriate, although the upper limit may be exceeded.
- the daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, as a continuous infusion. Single dose compositions can contain such amounts or submultiples thereof of the compound or composition to make up the daily dose.
- the dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.
- the compound is formulated as an oral dosage form.
- the antidepressant is formulated as an oral dosage form.
- the compound and the antidepressant are administered as a single dosage form.
- the compound and the antidepressant are orally administered as a single dosage form.
- PEH is formulated as an oral dosage form.
- the antidepressant is formulated as an oral dosage form.
- PEH and the antidepressant are administered as a single dosage form.
- PEH and the antidepressant are orally administered as a single dosage form.
- the compound is administered at a dose of from about 0.5 mg/kg/day to about 3 mg/kg/day, about 0.5 mg/kg/day to about 2.5 mg/kg/day, about 0.5 mg/kg/day to about 2 mg/kg/day, about 0.5 mg/kg/day to about 1.5 mg/kg/day, about 0.5 mg/kg/day to about 1 mg/kg/day, about 1 mg/kg/day to about 3 mg/kg/day, about 1.5 mg/kg/day to about 3 mg/kg/day, about 2 mg/kg/day to about 3 mg/kg/day, about 2.5 mg/kg/day to about 3 mg/kg/day, about 1 mg/kg/day to about 2.5 mg/kg/day, or about 1.5 mg/kg/day to about 2 mg/kg/day.
- PEH is administered at a dose of from about 0.5 mg/kg/day to about 3 mg/kg/day, about 0.5 mg/kg/day to about 2.5 mg/kg/day, about 0.5 mg/kg/day to about 2 mg/kg/day, about 0.5 mg/kg/day to about 1.5 mg/kg/day, about 0.5 mg/kg/day to about 1 mg/kg/day, about 1 mg/kg/day to about 3 mg/kg/day, about 1.5 mg/kg/day to about 3 mg/kg/day, about 2 mg/kg/day to about 3 mg/kg/day, about 2.5 mg/kg/day to about 3 mg/kg/day, about 1 mg/kg/day to about 2.5 mg/kg/day, or about 1.5 mg/kg/day to about 2 mg/kg/day.
- the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or buspirone.
- SSRI selective serotonin reuptake inhibitor
- SNRI serotonin-norepinephrine reuptake inhibitor
- TCA tricyclic antidepressant
- buspirone buspirone
- the antidepressant is a SSRI.
- SSRIs include, but are not limited to, citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
- the antidepressant is a SNRI.
- SNRIs include, but are not limited to, desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
- the antidepressant is a TCA.
- TCAs include, but are not limited to, amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
- the antidepressant is a 5HTIA receptor agonist .
- 5HTIA receptor agonists include, but are not limited to, buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone.
- the 5HTIA receptor agonist is buspirone.
- the psychological disorder is a severe anxiety disorder.
- severe anxiety disorders include, but are not limited to generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, depression with severe anxiety, and bipolar disorder with severe anxiety.
- GAD generalized anxiety disorder
- SAD seasonal affective disorder
- depression depression with severe anxiety
- bipolar disorder with severe anxiety.
- OCD obsessive-compulsive disorder
- the psychological disorder is depression.
- depression is treatment-resistant depression.
- the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
- adequate antidepressant treatments include, but are not limited to, administration of bupropion, a monoamine oxidase inhibitor, a SNRI, a SSRI, a TCA, nefazodone, trazodone, pramipexole, mirtazapine, or vortioxetin.
- the adequate treatment comprises administration of an agent selected from the group consisting of a SSRI, a SNRI, a TCA, a MAOI, and a 5HTIA receptor agonist.
- the subject has not responded to at least two adequate antidepressant treatments prior to the administering step.
- the two adequate antidepressant treatments comprise treatments with agents from two different classes of antidepressants.
- compositions comprising a compound having a structure: an antidepressant, and a pharmaceutically acceptable carrier, wherein at least one of the compound and the antidepressant is present in a therapeutically effective amount, or wherein the compound and the antidepressant are together present in a therapeutically effective amount.
- pharmaceutical compositions comprising the compound, a 5HTIA receptor agonist, and a pharmaceutically acceptable carrier, wherein at least one of the compound and the 5HTIA receptor agonist is present in a therapeutically effective amount, or wherein the compound and the 5HTIA receptor agonist are together present in a therapeutically effective amount.
- compositions comprising [3- phenylethylidenehydrazine (PEH), an antidepressant, and a pharmaceutically acceptable carrier, wherein at least one of PEH and the antidepressant is present in a therapeutically effective amount, or wherein PEH and the antidepressant are together present in a therapeutically effective amount.
- PEH phenylethylidenehydrazine
- the composition is formulated as an oral dosage form. In some aspects, the composition is formulated as a single oral dosage form.
- the compound is present in a therapeutically effective amount.
- the antidepressant is present in a therapeutically effective amount.
- the compound and the antidepressant are together present in a therapeutically effective amount.
- PEH is present in a therapeutically effective amount.
- the antidepressant is present in a therapeutically effective amount.
- PEH and the antidepressant are together present in a therapeutically effective amount.
- the antidepressant is a SSRI, a SNRI, a TCA, or a 5HTIA receptor agonist.
- the antidepressant is a SSRI.
- SSRIs include, but are not limited to, citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
- the antidepressant is a SNRI.
- SNRIs include, but are not limited to, desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
- the antidepressant is a TCA.
- TCAs include, but are not limited to, amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
- the antidepressant is a 5HTIA receptor agonist.
- 5HTIA receptor agonists include, but are not limited to, buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone.
- the 5HTIA receptor agonist is buspirone.
- the pharmaceutical compositions comprise the compounds in a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
- suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- the compounds can be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, Pa., 1995.
- the disclosed pharmaceutical compositions comprise the disclosed compounds (including pharmaceutically acceptable salt(s) thereof) as an active ingredient, a pharmaceutically acceptable carrier, and, optionally, other therapeutic ingredients or adjuvants.
- the instant compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
- the pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
- compositions of the present invention suitable for parenteral administration can be prepared as solutions or suspensions of the active compounds in water.
- a suitable surfactant can be included such as, for example, hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
- compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions.
- the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions.
- the final injectable form should be sterile and should be effectively fluid for easy syringability.
- the pharmaceutical compositions should be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
- compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, mouth washes, gargles, and the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations can be prepared, utilizing a compound of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
- compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories can be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
- the pharmaceutical compositions of this invention can include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of the compounds of the invention.
- the compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
- the pharmaceutical carrier employed can be, for example, a solid, liquid, or gas.
- solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid.
- liquid carriers are sugar syrup, peanut oil, olive oil, and water.
- gaseous carriers include carbon dioxide and nitrogen.
- any convenient pharmaceutical media can be employed.
- water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets.
- carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed.
- tablets can be coated by standard aqueous or nonaqueous techniques
- a tablet containing the composition of this invention can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets can be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- the pharmaceutical formulations described above can include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
- additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like.
- other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient
- the method of use is directed to the treatment of a disorder.
- the disclosed compounds can be used as single agents or in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of the aforementioned diseases, disorders and conditions for which the compound or the other drugs have utility, where the combination of drugs together are safer or more effective than either drug alone.
- the other drug(s) can be administered by a route and in an amount commonly used therefore, contemporaneously or sequentially with a disclosed compound.
- a pharmaceutical composition in unit dosage form containing such drugs and the disclosed compound is preferred.
- combination therapy can also be administered on overlapping schedules. It is also envisioned that the combination of one or more active ingredients and a disclosed compound can be more efficacious than either as a single agent.
- the pharmaceutical compositions and methods of the present invention can further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
- the invention relates to a method for the manufacture of a medicament for treating a psychological disorder in a mammal, the method comprising combining a therapeutically effective amount of PEH and an antidepressant with a pharmaceutically acceptable carrier or diluent.
- the present method includes the administration to an animal, particularly a mammal, and more particularly a human, of a therapeutically effective amount of the compound effective in the treatment of a psychological disorder, such as treatment resistant depression and other psychological disorders disclosed herein.
- a psychological disorder such as treatment resistant depression and other psychological disorders disclosed herein.
- the dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to affect a therapeutic response in the animal over a reasonable time frame.
- dosage will depend upon a variety of factors including the condition of the animal, the body weight of the animal, as well as the severity and stage of the disorder.
- the invention relates to the manufacture of a medicament comprising combining PEH, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, with an antidepressant and a pharmaceutically acceptable carrier or diluent.
- the invention relates to the uses of combination treatments for treating psychological disorders.
- the invention relates to the use of PEH and an antidepressant in the manufacture of a medicament for the treatment of a psychological disorder such as, for example, a severe anxiety disorder (e.g. , generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety) or obsessive-compulsive disorder (OCD).
- a severe anxiety disorder e.g. , generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety
- OCD obsessive-compulsive disorder
- the use relates to a process for preparing a pharmaceutical composition comprising a therapeutically effective amount of PEH and an antidepressant, and a pharmaceutically acceptable carrier, for use as a medicament.
- the use relates to a process for preparing a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of PEH and an antidepressant, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of PEH and an antidepressant.
- the use relates to the treatment of a psychological disorder in a vertebrate animal. In a further aspect, the use relates to the treatment of a psychological disorder in a human subject.
- a severe anxiety disorder e.g. , generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety
- OCD obsessive-compulsive disorder
- the disclosed uses can be employed in connection with the disclosed compounds, methods, compositions, and kits.
- the invention relates to the use of a disclosed compound or composition of a medicament for the treatment of a psychological disorder in a mammal.
- the invention relates to the use of a disclosed compound or composition in the manufacture of a medicament for the treatment of a psychological disorder such as, for example, a severe anxiety disorder (e.g., generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety) or obsessive-compulsive disorder (OCD).
- a severe anxiety disorder e.g., generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety
- OCD obsessive-compulsive disorder
- kits comprising a compound having a structure: and an antidepressant, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
- kits comprising the compound and a 5HTIA receptor agonist, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
- kits comprising PEH and an antidepressant, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
- kits comprising PEH and a 5HTIA receptor agonist, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
- the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or buspirone.
- SSRI selective serotonin reuptake inhibitor
- SNRI serotonin-norepinephrine reuptake inhibitor
- TCA tricyclic antidepressant
- buspirone buspirone
- the antidepressant is a SSRI.
- SSRIs include, but are not limited to, citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
- the antidepressant is a SNRI.
- SNRIs include, but are not limited to, desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
- the antidepressant is a TCA.
- TCAs include, but are not limited to, amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
- the antidepressant is a 5HTIA receptor agonist.
- 5HTIA receptor agonists include, but are not limited to, buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone.
- the 5HTIA receptor agonist is buspirone.
- the psychological disorder is a severe anxiety disorder.
- severe anxiety disorders include, but are not limited to generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder, depression, depression with severe anxiety, and bipolar disorder with severe anxiety.
- the psychological disorder is obsessive-compulsive disorder (OCD).
- the psychological disorder is depression.
- depression is treatment-resistant depression.
- the compound and the antidepressant are co-packaged. In some aspects, the compound and the antidepressant are co-formulated.
- PEH and the antidepressant are co-packaged. In some aspects, PEH and the antidepressant are co-formulated.
- the compound and the antidepressant are administered sequentially. In some aspects, the compound and the antidepressant are administered simultaneously.
- PEH and the antidepressant are administered sequentially. In some aspects, PEH and the antidepressant are administered simultaneously.
- the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises an effective amount of the compound and the antidepressant.
- the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises an effective amount of PEH and the antidepressant.
- the effective amount is a therapeutically effective amount.
- the effective amount is a prophylactically effective amount.
- each dose of the compound and the antidepressant are coformulated.
- each dose of the compound and the antidepressant are copackaged.
- each dose of PEH and the antidepressant are co-formulated. In a still further aspect, each dose of PEH and the antidepressant are co-packaged.
- each dose of the compound and the antidepressant are administered sequentially. In a still further aspect, each dose of the compound and the antidepressant are administered simultaneously.
- each dose of PEH and the antidepressant are administered sequentially. In a still further aspect, each dose of PEH and the antidepressant are administered simultaneously.
- the dosage forms are formulated for oral administration, inhalation, topical administration, and/or parenteral administration.
- the dosage form for the compound is formulated for oral administration and the dosage form for the antidepressant is formulated for parental administration.
- the dosage form for the compound is formulated for parental administration and the dosage form for the antidepressant is formulated for oral administration.
- the dosage form for the compound is formulated for topical administration and the dosage form for the antidepressant is formulated for parental administration.
- the dosage form for the compound is formulated for parental administration and the dosage form for the antidepressant is formulated for topical administration.
- the dosage form for the compound is formulated for oral administration and the dosage form for the antidepressant is formulated for inhalation.
- the dosage form for the compound is formulated for inhalation and the dosage form for the antidepressant is formulated for oral administration.
- the dosage form for the compound is formulated for topical administration and the dosage form for the antidepressant is formulated for inhalation.
- the dosage form for the compound is formulated for inhalation and the dosage form for the antidepressant is formulated for topical administration.
- the dosage form for PEH is formulated for oral administration and the dosage form for the antidepressant is formulated for parental administration.
- the dosage form for PEH is formulated for parental administration and the dosage form for the antidepressant is formulated for oral administration.
- the dosage form for PEH is formulated for topical administration and the dosage form for the antidepressant is formulated for parental administration.
- the dosage form for PEH is formulated for parental administration and the dosage form for the antidepressant is formulated for topical administration.
- the dosage form for PEH is formulated for oral administration and the dosage form for the antidepressant is formulated for inhalation.
- the dosage form for PEH is formulated for inhalation and the dosage form for the antidepressant is formulated for oral administration.
- the dosage form for PEH is formulated for topical administration and the dosage form for the antidepressant is formulated for inhalation.
- the dosage form for PEH is formulated for inhalation and the dosage form for the antidepressant is formulated for topical administration.
- kits can be prepared from the disclosed compounds, products, and pharmaceutical compositions. It is also understood that the disclosed kits can be employed in connection with the disclosed methods of using.
- the subject of the herein disclosed methods is a vertebrate, e.g., a mammal.
- the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent.
- the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
- a patient refers to a subject afflicted with a disease or disorder.
- patient includes human and veterinary subjects.
- the subject has been diagnosed with a need for treatment prior to the administering step. In some aspects of the disclosed method, the subject has been diagnosed with a psychological disorder prior to the administering step. In some aspects of the disclosed methods, the subject has been identified with a need for treatment prior to the administering step. In one aspect, a subject can be treated prophylactically with a compound or composition disclosed herein, as discussed herein elsewhere. a. DOSAGE
- Toxicity and therapeutic efficacy of the agents and pharmaceutical compositions described herein can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LDso (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50.
- Polypeptides or other compounds that exhibit large therapeutic indices are preferred.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity, and with little or no adverse effect on a human's ability to hear.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (that is, the concentration of the test compound which achieves a half- maximal inhibition of symptoms) as determined in cell culture.
- Exemplary dosage amounts of a differentiation agent are at least from about 0.01 to 3000 mg per day, e.g, at least about 0.00001, 0.0001, 0.001, 0.01, 0.1, 1, 2, 5, 10, 25, 50, 100, 200, 500, 1000, 2000, or 3000 mg per kg per day, or more.
- the formulations and routes of administration can be tailored to the disease or disorder being treated, and for the specific human being treated.
- a subject can receive a dose of the agent once or twice or more daily for one week, one month, six months, one year, or more.
- the treatment can continue indefinitely, such as throughout the lifetime of the human.
- Treatment can be administered at regular or irregular intervals (once every other day or twice per week), and the dosage and timing of the administration can be adjusted throughout the course of the treatment.
- the dosage can remain constant over the course of the treatment regimen, or it can be decreased or increased over the course of the treatment.
- the dosage facilitates an intended purpose for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation or allergic response.
- undesirable side effects such as toxicity, irritation or allergic response.
- human doses can readily be extrapolated from animal studies (Katocs et al., (1990) Chapter 27 in Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA).
- the dosage required to provide an effective amount of a formulation will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) (Nies et al., (1996) Chapter 3, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY). b. ROUTES OF ADMINISTRATION
- routes of administering the disclosed compounds and compositions can be administered by direct therapy using systemic administration and/or local administration.
- the route of administration can be determined by a patient's health care provider or clinician, for example following an evaluation of the patient.
- an individual patient's therapy may be customized, e.g, the type of agent used, the routes of administration, and the frequency of administration can be personalized.
- therapy may be performed using a standard course of treatment, e.g. , using pre-selected agents and pre-selected routes of administration and frequency of administration.
- Systemic routes of administration can include, but are not limited to, parenteral routes of administration, e.g, intravenous injection, intramuscular injection, and intraperitoneal injection; enteral routes of administration e.g, administration by the oral route, lozenges, compressed tablets, pills, tablets, capsules, drops (e.g. , ear drops), syrups, suspensions and emulsions; rectal administration, e.g, a rectal suppository or enema; a vaginal suppository; a urethral suppository; transdermal routes of administration; and inhalation (e.g, nasal sprays).
- parenteral routes of administration e.g, intravenous injection, intramuscular injection, and intraperitoneal injection
- enteral routes of administration e.g, administration by the oral route, lozenges, compressed tablets, pills, tablets, capsules, drops (e.g. , ear drops), syrups, suspensions and emulsions
- rectal administration e.g
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides compositions and methods for the treatment of anxiety, panic disorder, seasonal affective disorder (SAD), and other psychological disorders. In particular, the invention provides combination treatment methods involving administration of phenylethylidenehydrazine or a pharmaceutically acceptable salt or prodrug thereof and an antidepressant. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Description
PHENYLETHYLIDENEHYDRAZINE COMBINATION THERAPIES
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This Application claims the benefit of U.S. Application No. 63/143,556, filed on January 29, 2021, and U.S. Application No. 63/236,061, filed on August 23, 2021, the contents of both of which are incorporated herein by reference in their entireties.
BACKGROUND
[0001] Anxiety disorders such as generalized anxiety disorder (GAD), seasonal affective disorder (SAD), depression, and panic disorder are the most common mental health concern in the United States today. See, e.g., Bystritsky, A. (2006) Molecular Psychiatry 11(9): 805- 814; Buigues and Vallego (1987) The Journal of Clinical Psychiatry 48(2): 55-59; Blanco et al. (2003) Depression and Anxiety 18(1): 29-40. Over 19% of adults in the United States have an anxiety disorder, and approximately 7% of children aged 3-17 experience issues with anxiety each year. Most people develop symptoms before age 21. Anxiety disorders are a group of related conditions with unique symptoms; however, all anxiety disorders have one thing in common: persistent, excessive fear or worry in situations that are not threatening. Typically, individuals experience one or more of the following symptoms: feelings of apprehension or dread, feeling tense or jumpy, restlessness or irritability, anticipating the worst and being watchful for signs of danger, pounding or racing heart and shortness of breath, sweating, tremors, twitches, headaches, fatigue, insomnia, upset stomach, frequent urination, and diarrhea.
[0002] Depression is among the most disabling of all medical disorders, with a lifetime prevalence of approximately 17%. It frequently appears early in life, can run a chronic course, and can adversely affect the prognosis of other medical illnesses, such as coronary vascular disease, diabetes, and osteoporosis. Depression is characterized by a depressed mood, and markedly diminished interest or pleasure in activities. Other symptoms include significant weight loss or weight gain, decrease or increase in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or excessive or inappropriate guilt, diminished ability to think or concentrate or indecisiveness, recurrent thoughts of death, and suicidal ideation or suicidal attempts. Depression can vary in severity from mild to very severe. It is most often episodic but can be recurrent or chronic. Some people have only a single episode, with a full return to premorbid
function. Failures of first treatments are common and, more than 50 percent of those who initially suffer a single major depressive episode eventually develop another.
[0003] Current treatment options for depression include monotherapy or combination therapy with various classes of drugs such as, for example, serotonin specific reuptake inhibitors (SSRIs), serotonin noradrenergic reuptake inhibitors (SNRIs), norepinephrinedopamine reuptake inhibitors (NDRIs), mono-amine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), anti-psychotics, “natural products” (e.g, Kava-Kava, St. John's Wort), dietary supplement (e.g, s-adenosylmethionine), and others. Unfortunately, in the clinic, 40-50% of depressed patients who are initially prescribed antidepressant therapy do not experience a timely remission of depression symptoms. This group typifies level 1 treatment-resistant depression, which is characterized by a failure to demonstrate an “adequate” response to an “adequate” treatment trial (that is, sufficient intensity of treatment for sufficient duration). Moreover, about approximately 30% of depressed patients remain partially or totally treatment-resistant to at least two antidepressant treatments including combination treatments. TRD is characterized with low remission rates and partial response to treatment, often requiring a changing combination of several drugs to improve short- or medium-term response. Some TRD patients resort to Transcranial Magnetic Stimulation (TMS), which enhances response in about 30% of subjects, and Electroconvulsive Therapy (ECT), which produces response in about 50% of TRD patients with relapse probability increasing with time and reaching approximately 50% within a year. Both TMS and ECT require concurrent continuous use of “maintenance” anti-depressant medication. More recently, ketamine has been used as an anti-depressant treatment. The FDA approved esketamine treatment has a rapid response that is particularly useful for acutely suicidal patients, although clinical trials of esketamine have shown a minimal improvement in depression rating scales compared to placebo.
[0004] The vast majority of antidepressants manipulate monoamine neurotransmitters, particularly serotonin and norepinephrine, and, sometimes, dopamine. However, newer research has suggested a role for the inhibitory neurotransmitter GABA (gamma- aminobutyric acid) in treating both anxiety and depression. See, e.g, Matveychuk et al. (2013) Journal of Neural Transmission 120(6): 987-996.
[0005] Accordingly, there remains a need for compositions and methods for treating psychological disorders such as severe anxiety disorders, and, in particular, for treating generalized anxiety disorder, panic disorder, seasonal affective disorder, and treatmentresistant depression. These needs and others are met by the present invention.
SUMMARY
[0006] In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to methods for treating psychological disorders such as, for example, severe anxiety disorders (e.g., generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety) and obsessive-compulsive disorder (OCD) using phenylethylidenehydrazine (PEH) or a pharmaceutically acceptable salt or prodrug thereof, a GABA transaminase enzyme inhibitor, in combination with an antidepressant, compositions comprising PEH or a salt or prodrug thereof and an antidepressant, and methods of making and using same. Without wishing to be bound by theory, the disclosed methods introduce a treatment that potentiates levels of monoamine neurotransmitters, as well as GABA levels, which beneficially enhances the effectiveness of anti-depressant therapy, while also simultaneously treating concomitant anxiety symptoms.
[0007] Thus, disclosed are methods for treating a psychological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of phenylethylidenehydrazine (PEH) or a pharmaceutically acceptable salt thereof, and an antidepressant.
[0008] Also disclosed are methods for treating a psychological disorder in a subject, the method comprising administering to the subject an effective amount of PEH or a pharmaceutically acceptable salt thereof, and a 5HTIA receptor agonist.
[0009] Also disclosed are methods for treating treatment-resistant depression in a human subject in need thereof, the method comprising orally administering to the subject an effective amount of PEH or a pharmaceutically acceptable salt thereof, and an antidepressant, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
[0010] Also disclosed are methods for treating treatment-resistant depression in a human subject in need thereof, the method comprising orally administering to the subject an effective amount of PEH or a pharmaceutically acceptable salt thereof, and a 5HTIA receptor agonist, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
[0011] Also disclosed are pharmaceutical compositions comprising PEH or a pharmaceutically acceptable salt thereof, an antidepressant, and a pharmaceutically
acceptable carrier, wherein at least one of PEH or the pharmaceutically acceptable salt thereof and the antidepressant is present in a therapeutically effective amount, or wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are together present in a therapeutically effective amount.
[0012] Also disclosed are pharmaceutical compositions comprising PEH or a pharmaceutically acceptable salt thereof, a 5HTIA receptor agonist, and a pharmaceutically acceptable carrier, wherein at least one of PEH or the pharmaceutically acceptable salt thereof and the 5HTIA receptor agonist is present in a therapeutically effective amount, or wherein PEH or the pharmaceutically acceptable salt thereof and the 5HTIA receptor agonist are together present in a therapeutically effective amount.
[0013] Also disclosed are kits comprising PEH or a pharmaceutically acceptable salt thereof, and an antidepressant, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
[0014] Also disclosed are kits comprising PEH or a pharmaceutically acceptable salt thereof, and a 5HTIA receptor agonist, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
[0015] While aspects of the present invention can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of the present invention can be described and claimed in any statutory class. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain the principles of the invention.
[0017] FIG. 1 shows representative data illustrating the average systolic blood pressure (SBP) increase observed when taking a variety of drugs with 40 mg of tyramine taken with a meal.
[0018] FIG. 2 shows representative data illustrating that a postural drop in SBP is highly correlated with TCP plasma concentration.
[0019] Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or can be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
DETAILED DESCRIPTION
[0020] The present invention can be understood more readily by reference to the following detailed description of the invention and the Examples included therein.
[0021] Before the present compounds, compositions, articles, systems, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.
[0022] While aspects of the present invention can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of the present invention can be described and claimed in any statutory class. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[0023] Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided herein may be different from the actual publication dates, which can require independent confirmation.
A. DEFINITIONS
[0024] As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an antidepressant,” “a psychological disorder,” or “a subject” includes mixtures of two or more such antidepressants, psychological disorders, or subjects, and the like.
[0025] As used in the specification and in the claims, the term “comprising” can include the aspects “consisting of’ and “consisting essentially of.”
[0026] Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0027] As used herein, the terms “about” and “at or about” mean that the amount or value in question can be the value designated some other value approximately or about the same. It is generally understood, as used herein, that it is the nominal value indicated ±10% variation unless otherwise indicated or inferred. The term is intended to convey that similar values promote equivalent results or effects recited in the claims. That is, it is understood that
amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but can be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art. In general, an amount, size, formulation, parameter or other quantity or characteristic is “about” or “approximate” whether or not expressly stated to be such. It is understood that where “about” is used before a quantitative value, the parameter also includes the specific quantitative value itself, unless specifically stated otherwise.
[0028] References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
[0029] A weight percent (wt. %) of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
[0030] As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0031] As used herein, the term “subject” can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Thus, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. In one aspect, the subject is a mammal. A patient refers to a subject afflicted with a disease or disorder. The term “patient” includes human and veterinary subjects.
[0032] As used herein, the term “treatment” refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the
curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various aspects, the term covers any treatment of a subject, including a mammal (e.g, a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease. In one aspect, the subject is a mammal such as a primate, and, in a further aspect, the subject is a human. The term “subject” also includes domesticated animals (e.g, cats, dogs, etc.), livestock (e.g, cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g, mouse, rabbit, rat, guinea pig, fruit fly, etc.).
[0033] As used herein, the term “prevent” or “preventing” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. [0034] As used herein, the term “diagnosed” means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the compounds, compositions, or methods disclosed herein. [0035] As used herein, the terms “administering” and “administration” refer to any method of providing a pharmaceutical preparation to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
[0036] As used herein, the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired
condition. For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition.
[0037] As used herein, “dosage form” means a pharmacologically active material in a medium, carrier, vehicle, or device suitable for administration to a subject. A dosage form can comprise a disclosed compound, a product of a disclosed method of making, or a salt, solvate, or polymorph thereof, in combination with a pharmaceutically acceptable excipient, such as a preservative, buffer, saline, or phosphate buffered saline. Dosage forms can be made using conventional pharmaceutical manufacturing and compounding techniques. Dosage forms can comprise inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants (e.g., ascorbic acid, alpha-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene9-10 nonyl phenol, sodium desoxycholate), solution and/or cryo/lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic adjustment agents (e.g., salts or sugars), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsilozone), preservatives (e.g., thimerosal, 2-
phenoxyethanol, EDTA), polymeric stabilizers and viscosity-adjustment agents (e.g., polyvinylpyrrolidone, poloxamer 488, carboxymethylcellulose) and co-solvents (e.g., glycerol, polyethylene glycol, ethanol). A dosage form formulated for injectable use can have a disclosed compound, a product of a disclosed method of making, or a salt, solvate, or polymorph thereof, suspended in sterile saline solution for injection together with a preservative.
[0038] As used herein, “kit” means a collection of at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose. Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation.
[0039] As used herein, “instruction(s)” means documents describing relevant materials or methodologies pertaining to a kit. These materials may include any combination of the following: background information, list of components and their availability information (purchase information, etc.), brief or detailed protocols for using the kit, trouble-shooting, references, technical support, and any other related documents. Instructions can be supplied with the kit or as a separate member component, either as a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. Instructions can comprise one or multiple documents, and are meant to include future updates.
[0040] As used herein, the terms “therapeutic agent” include any synthetic or naturally occurring biologically active compound or composition of matter which, when administered to an organism (human or nonhuman animal), induces a desired pharmacologic, immunogenic, and/or physiologic effect by local and/or systemic action. The term therefore encompasses those compounds or chemicals traditionally regarded as drugs, vaccines, and biopharmaceuticals including molecules such as proteins, peptides, hormones, nucleic acids, gene constructs and the like. Examples of therapeutic agents are described in well-known literature references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and The Pharmacological Basis of Therapeutics (12th edition) , and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances that
affect the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. For example, the term “therapeutic agent” includes compounds or compositions for use in all of the major therapeutic areas including, but not limited to, adjuvants; anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations, anorexics, anti-inflammatory agents, anti-epileptics, local and general anesthetics, hypnotics, sedatives, antipsychotic agents, neuroleptic agents, antidepressants, anxiolytics, antagonists, neuron blocking agents, anticholinergic and cholinomimetic agents, antimuscarinic and muscarinic agents, antiadrenergics, antiarrhythmics, antihypertensive agents, hormones, and nutrients, antiarthritics, antiasthmatic agents, anticonvulsants, antihistamines, antinauseants, antineoplastics, antipruritics, antipyretics; antispasmodics, cardiovascular preparations (including calcium channel blockers, beta-blockers, beta-agonists and antiarrythmics), antihypertensives, diuretics, vasodilators; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones; bone growth stimulants and bone resorption inhibitors; immunosuppressives; muscle relaxants; psychostimulants; sedatives; tranquilizers; proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced); and nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA) including both double- and single-stranded molecules, gene constructs, expression vectors, antisense molecules and the like), small molecules (e.g, doxorubicin) and other biologically active macromolecules such as, for example, proteins and enzymes. The agent may be a biologically active agent used in medical, including veterinary, applications and in agriculture, such as with plants, as well as other areas. The term "therapeutic agent" also includes without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of disease or illness; or substances which affect the structure or function of the body; or pro- drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment.
[0041] The term “pharmaceutically acceptable” describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.
[0042] As used herein, the term “derivative” refers to a compound having a structure derived from the structure of a parent compound (e.g, PEH) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be
expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds. Exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound.
[0043] As used herein, the term “pharmaceutically acceptable carrier” refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions, which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
B. METHODS FOR TREATING A PSYCHOLOGICAL DISORDER
[0044] Phenelzine (PLZ) is a potent irreversible, non-selective monoamine oxidase inhibitor (MAOI). It is used clinically for the treatment of a number of psychiatric disorders,
including major depression (McGrath, et al. 1986), atypical depression (Paykel, et al. 1982), and social anxiety disorder (Liebowitz, et al. 1988). Interestingly, PLZ is also an inhibitor of y-aminobutyric acid (GABA) and alanine (ALA), presumably due to its inhibition of GABA transaminase and ALA transaminase, respectively ((Popov and Matthies (1969) J Neurochem 16(3): 899-907; Paslawski, et al. (1995) Prog Brain Res 106: 181-186). It has been suggested that a metabolite of PLZ formed by the action of monoamine oxidase (MAO) is primarily responsible for these beneficial effects, since PLZ-induced increases in GABA and ALA can be abolished by pre-treating the animals with another MAO inhibitor (Popov and Matthies (1969; Todd and Baker (1995) J Affect Disord 35: 125-129; MacKenzie, et al. (2009) “Neurochemical and neuroprotective aspects of phenelzine and its active metabolite [3- phenylethylidenehydrazine,” University of Alberta, Dissertation). This metabolite has since been identified as PEH (MacKenzie (2009)).
PLZ Prodrug PEH Prodrug
[0046] As would be understood by one of ordinary skill in the art, the disclosed prodrugs would be present with a counterion. Exemplary counterions are well-known by those of ordinary skill in the art, and include, but are not limited to, halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid. Thus, in various aspects, a PLZ prodrug and a PEH prodrug can be present as follows:
PLZ Prodrug PEH Prodrug in which X is a counterion, such as, for example, halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate,
malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid.
[0047] Although PEH and PLZ share many pharmacological properties, an important distinction is that PEH is only a weak and transient inhibitor of MAO-A and MAO-B (Paslawski, et al. (2001) Drug Dev Res 54: 35-39; MacKenzie, et al. (2008) BioorgMed Chem 16(17): 8254-8263). A major drawback to clinical use of PLZ is a potential interaction with tyramine-containing foods such as aged cheeses and meats, overripe fruits and vegetables, and fermented beverages. By irreversibly inhibiting MAO-A in the gut, PLZ prevents the metabolism of dietary tyramine, a sympathomimetic agent, which can then enter the bloodstream and cause unpleasant symptoms ranging from headache to hypertensive crisis. Notably, because PEH is a poor inhibitor of MAO-A, it should not be associated with this adverse effect.
[0048] Without wishing to be bound by theory, it is expected that the combination of PEH or a pharmaceutically acceptable salt or prodrug thereof and an antidepressant such as, for example, a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or a 5HTIA receptor agonist, can beneficially be useful for treating psychological disorders via two distinct mechanisms (e.g. , potentiation of both GABA and serotonin), and, in some aspects, can result in a synergistic effect. This combination is advantageous in that neither of these drugs is suspected of having long-term side effects, leading to addiction, or generating tolerance. Further, as detailed above, administration of PEH, specifically, avoids the negative interactions triggered by tyramine-rich foods, while also still maintaining the beneficial effects on GABA.
[0049] Thus, in one aspect, disclosed are methods for treating a psychological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of PEH or a pharmaceutically acceptable salt thereof, and an antidepressant. In a further aspect, the pharmaceutically acceptable salt is a compound having a structure:
wherein X is a counterion. Exemplary counterions include, but are not limited to, halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid. In a still further aspect, the pharmaceutically acceptable salt is a Lewis acid-base adduct. In yet a
further aspect, the Lewis acid-base adduct is a compound having a structure represented by a formula:
wherein X’ is a residue of a Lewis acid such as, for example, a non-Bronsted acid. Examples of residues of Lewis acids include, but are not limited to, -BF3 and -A1CL.
[0050] In one aspect, disclosed are methods for treating a psychological disorder in a subject, the method comprising administering to the subject an effect amount of a compound having a structure:
and an antidepressant. In one aspect, disclosed are methods for treating a psychological disorder in a subject, the method comprising administering to the subject an effective amount of the compound and a 5HTIA receptor agonist.
[0051] In one aspect, disclosed are methods for treating a psychological disorder in a subject, the method comprising administering to the subject an effective amount of PEH and an antidepressant. In one aspect, disclosed are methods for treating a psychological disorder in a subject, the method comprising administering to the subject an effective amount of PEH and a 5HTIA receptor agonist.
[0052] In one aspect, disclosed are methods for treating treatment-resistant depression in a human subject, the method comprising orally administering to the subject an effective amount of a compound having a structure:
and an antidepressant, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step. In one aspect, disclosed are methods for treating treatment-resistant depression in a human subject, the method comprising orally administering to the subject an effective amount of the compound and a 5HTIA receptor agonist, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
[0053] In one aspect, disclosed are methods for treating treatment-resistant depression in a human subject, the method comprising orally administering to the subject an effective amount of PEH and an antidepressant, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step. In one aspect, disclosed are
methods for treating treatment-resistant depression in a human subject, the method comprising orally administering to the subject an effective amount of PEH and a 5HTIA receptor agonist, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
[0054]
[0055] In some aspects, the method comprises administering a pharmaceutical composition comprising an effective amount of the compound. In a further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of the compound and the antidepressant. In a still further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of the compound and a 5HTIA receptor agonist.
[0056] In some aspects, the method comprises administering a pharmaceutical composition comprising an effective amount of PEH. In a further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of PEH and the antidepressant. In a still further aspect, the method comprises administering a pharmaceutical composition comprising an effective amount of PEH and a 5HTIA receptor agonist.
[0057] In some aspects, the method comprises administering a single dose of the compound. In a further aspect, the method comprises administering multiple doses of the compound.
[0058] In some aspects, the method comprises administering a single dose of PEH. In a further aspect, the method comprises administering multiple doses of PEH.
[0059] In some aspects, a single administration of the compound is sufficient to alleviate symptoms of the psychological disorder for a period of at least 4 hours, at least 6 hours, at least 8 hours, or at least 10 hours.
[0060] In some aspects, a single administration of PEH is sufficient to alleviate symptoms of the psychological disorder for a period of at least 4 hours, at least 6 hours, at least 8 hours, or at least 10 hours.
[0061] In some aspects, the compound and the antidepressant are administered sequentially. In a further aspect, the compound is administered prior to administration of the antidepressant. In a still further aspect, the compound is administered subsequent to administration of the antidepressant.
[0062] In some aspects, PEH and the antidepressant are administered sequentially. In a further aspect, PEH is administered prior to administration of the antidepressant. In a still further aspect, PEH is administered subsequent to administration of the antidepressant.
[0063] In some aspects, the compound and the antidepressant are administered simultaneously.
[0064] In some aspects, PEH and the antidepressant are administered simultaneously.
[0065] To treat or control the disorder, the compounds and pharmaceutical compositions comprising the compounds are administered to a subject in need thereof. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. The subject is preferably a mammal, such as a human. Prior to administering the compounds or compositions, the subject can be diagnosed with a need for treatment of a psychiatric disorder, such as depression.
[0066] Thus, in some aspects, the subject is a mammal. In a further aspect, the mammal is a human.
[0067] In some aspects, the subject has been diagnosed as having the psychological disorder prior to the administering step. In a further aspect, the subject has not been diagnosed as having a seizure disorder, a developmental disorder, a neurological disorder, a behavioral disorder, or addiction prior to the administering step. In a still further aspect, the subject has not been diagnosed as having a disorder associated with depression (i.e., a disorder that is a comorbidity with depression) such as, for example, addiction, a substance use disorder (e.g., alcohol use disorder, nicotine use disorder), a personality disorder (e.g, borderline personality disorder), post-traumatic stress disorder, and obsessive-compulsive disorder.
[0068] In some aspects, the method further comprises identifying a subject in need of treatment of a psychological disorder.
[0069] The compounds or compositions can be administered to the subject according to any method. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent. A preparation can be administered therapeutically; that is, administered to treat an existing disease or
condition. A preparation can also be administered prophylactically; that is, administered for prevention of an infection or condition, such as a psychiatric disorder.
[0070] In some aspects, the compound and the antidepressant are together present in an effective amount. In a further aspect, the compound and the antidepressant are each present in individually effective amounts. In a still further aspect, the compound is present in an individually effective amount. In yet a further aspect, the antidepressant is present in an individually effective amount.
[0071] In some aspects, PEH and the antidepressant are together present in an effective amount. In a further aspect, PEH and the antidepressant are each present in individually effective amounts. In a still further aspect, PEH is present in an individually effective amount. In yet a further aspect, the antidepressant is present in an individually effective amount.
[0072] In some aspects, the effective amount is a prophylactically effective amount. In a further aspect, the effective amount is a therapeutically effective amount.
[0073] The therapeutically effective amount or dosage of the compound can vary within wide limits. Such a dosage is adjusted to the individual requirements in each particular case including the specific compound(s) being administered, the route of administration, the condition being treated, as well as the patient being treated. In general, in the case of oral or parenteral administration to adult humans weighing approximately 70 Kg or more, a daily dosage of about 10 mg to about 1000 mg, preferably from about 20 mg to about 800 mg, should be appropriate, although the upper limit may be exceeded. The daily dosage can be administered as a single dose or in divided doses, or for parenteral administration, as a continuous infusion. Single dose compositions can contain such amounts or submultiples thereof of the compound or composition to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. [0074] In some aspects, the compound is formulated as an oral dosage form. In a further aspect, the antidepressant is formulated as an oral dosage form. In a still further aspect, the compound and the antidepressant are administered as a single dosage form. In yet a further aspect, the compound and the antidepressant are orally administered as a single dosage form. [0075] In some aspects, PEH is formulated as an oral dosage form. In a further aspect, the antidepressant is formulated as an oral dosage form. In a still further aspect, PEH and the antidepressant are administered as a single dosage form. In yet a further aspect, PEH and the antidepressant are orally administered as a single dosage form.
[0076] In some aspects, the compound is administered at a dose of from about 0.5 mg/kg/day to about 3 mg/kg/day, about 0.5 mg/kg/day to about 2.5 mg/kg/day, about 0.5 mg/kg/day to about 2 mg/kg/day, about 0.5 mg/kg/day to about 1.5 mg/kg/day, about 0.5 mg/kg/day to about 1 mg/kg/day, about 1 mg/kg/day to about 3 mg/kg/day, about 1.5 mg/kg/day to about 3 mg/kg/day, about 2 mg/kg/day to about 3 mg/kg/day, about 2.5 mg/kg/day to about 3 mg/kg/day, about 1 mg/kg/day to about 2.5 mg/kg/day, or about 1.5 mg/kg/day to about 2 mg/kg/day.
[0077] In some aspects, PEH is administered at a dose of from about 0.5 mg/kg/day to about 3 mg/kg/day, about 0.5 mg/kg/day to about 2.5 mg/kg/day, about 0.5 mg/kg/day to about 2 mg/kg/day, about 0.5 mg/kg/day to about 1.5 mg/kg/day, about 0.5 mg/kg/day to about 1 mg/kg/day, about 1 mg/kg/day to about 3 mg/kg/day, about 1.5 mg/kg/day to about 3 mg/kg/day, about 2 mg/kg/day to about 3 mg/kg/day, about 2.5 mg/kg/day to about 3 mg/kg/day, about 1 mg/kg/day to about 2.5 mg/kg/day, or about 1.5 mg/kg/day to about 2 mg/kg/day.
[0078] In some aspects, the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or buspirone.
[0079] Thus, in various aspects, the antidepressant is a SSRI. Examples of SSRIs include, but are not limited to, citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
[0080] In various aspects, the antidepressant is a SNRI. Examples of SNRIs include, but are not limited to, desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
[0081] In various aspects, the antidepressant is a TCA. Examples of TCAs include, but are not limited to, amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
[0082] In various aspects, the antidepressant is a 5HTIA receptor agonist . Examples of 5HTIA receptor agonists include, but are not limited to, buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone. In a further aspect, the 5HTIA receptor agonist is buspirone.
[0083] In some aspects, the psychological disorder is a severe anxiety disorder. Examples of severe anxiety disorders include, but are not limited to generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, depression with severe anxiety, and bipolar disorder with severe anxiety.
[0084] In some aspects, the psychological disorder is obsessive-compulsive disorder (OCD).
[0085] In some aspects, the psychological disorder is depression. In a further aspect, depression is treatment-resistant depression.
[0086] In some aspects, the subject has not responded to at least one adequate antidepressant treatment prior to the administering step. Examples of adequate antidepressant treatments include, but are not limited to, administration of bupropion, a monoamine oxidase inhibitor, a SNRI, a SSRI, a TCA, nefazodone, trazodone, pramipexole, mirtazapine, or vortioxetin. In a further aspect, the adequate treatment comprises administration of an agent selected from the group consisting of a SSRI, a SNRI, a TCA, a MAOI, and a 5HTIA receptor agonist.
[0087] In some aspects, the subject has not responded to at least two adequate antidepressant treatments prior to the administering step. In a further aspect, the two adequate antidepressant treatments comprise treatments with agents from two different classes of antidepressants.
C. PHARMACEUTICAL COMPOSITIONS COMPRISING PEH AND AN ANTIDEPRESSANT
[0088] In one aspect, disclosed are pharmaceutical compositions comprising a compound having a structure:
an antidepressant, and a pharmaceutically acceptable carrier, wherein at least one of the compound and the antidepressant is present in a therapeutically effective amount, or wherein the compound and the antidepressant are together present in a therapeutically effective amount. In one aspect, disclosed are pharmaceutical compositions comprising the compound, a 5HTIA receptor agonist, and a pharmaceutically acceptable carrier, wherein at least one of the compound and the 5HTIA receptor agonist is present in a therapeutically effective amount, or wherein the compound and the 5HTIA receptor agonist are together present in a therapeutically effective amount.
[0089] In one aspect, disclosed are pharmaceutical compositions comprising [3- phenylethylidenehydrazine (PEH), an antidepressant, and a pharmaceutically acceptable carrier, wherein at least one of PEH and the antidepressant is present in a therapeutically
effective amount, or wherein PEH and the antidepressant are together present in a therapeutically effective amount.
[0090] In some aspects, the composition is formulated as an oral dosage form. In some aspects, the composition is formulated as a single oral dosage form.
[0091] In some aspects, the compound is present in a therapeutically effective amount. In some aspects, the antidepressant is present in a therapeutically effective amount. In a still further aspect, the compound and the antidepressant are together present in a therapeutically effective amount.
[0092] In some aspects, PEH is present in a therapeutically effective amount. In some aspects, the antidepressant is present in a therapeutically effective amount. In a still further aspect, PEH and the antidepressant are together present in a therapeutically effective amount. [0093] In some aspects, the antidepressant is a SSRI, a SNRI, a TCA, or a 5HTIA receptor agonist.
[0094] Thus, in various aspects, the antidepressant is a SSRI. Examples of SSRIs include, but are not limited to, citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
[0095] In various aspects, the antidepressant is a SNRI. Examples of SNRIs include, but are not limited to, desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
[0096] In various aspects, the antidepressant is a TCA. Examples of TCAs include, but are not limited to, amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
[0097] In various aspects, the antidepressant is a 5HTIA receptor agonist. Examples of 5HTIA receptor agonists include, but are not limited to, buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone. In a further aspect, the 5HTIA receptor agonist is buspirone.
[0098] The pharmaceutical compositions comprise the compounds in a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. The compounds can be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and
excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, Pa., 1995.
[0099] In various aspects, the disclosed pharmaceutical compositions comprise the disclosed compounds (including pharmaceutically acceptable salt(s) thereof) as an active ingredient, a pharmaceutically acceptable carrier, and, optionally, other therapeutic ingredients or adjuvants. The instant compositions include those suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions can be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
[0100] Pharmaceutical compositions of the present invention suitable for parenteral administration can be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.
[0101] Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form should be sterile and should be effectively fluid for easy syringability. The pharmaceutical compositions should be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
[0102] Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, mouth washes, gargles, and the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations can be prepared, utilizing a compound of the invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an example, a cream or ointment is prepared by mixing hydrophilic material and water,
together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.
[0103] Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories can be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.
[0104] In various aspects, the pharmaceutical compositions of this invention can include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of the compounds of the invention. The compounds of the invention, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.
[0105] The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[0106] In preparing the compositions for oral dosage form, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by standard aqueous or nonaqueous techniques
[0107] A tablet containing the composition of this invention can be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets can be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
[0108] In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above can include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of the invention, and/or pharmaceutically acceptable salts thereof, can also be prepared in powder or liquid concentrate form.
D. ADDITIONAL METHODS OF USING THE COMPOSITIONS
[0109] Provided are methods of using of a disclosed composition or medicament. In one aspect, the method of use is directed to the treatment of a disorder. In a further aspect, the disclosed compounds can be used as single agents or in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of the aforementioned diseases, disorders and conditions for which the compound or the other drugs have utility, where the combination of drugs together are safer or more effective than either drug alone. The other drug(s) can be administered by a route and in an amount commonly used therefore, contemporaneously or sequentially with a disclosed compound. When a disclosed compound is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such drugs and the disclosed compound is preferred. However, the combination therapy can also be administered on overlapping schedules. It is also envisioned that the combination of one or more active ingredients and a disclosed compound can be more efficacious than either as a single agent. [0110] The pharmaceutical compositions and methods of the present invention can further comprise other therapeutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions.
1. MANUFACTURE OF A MEDICAMENT
[0111] In one aspect, the invention relates to a method for the manufacture of a medicament for treating a psychological disorder in a mammal, the method comprising combining a therapeutically effective amount of PEH and an antidepressant with a pharmaceutically acceptable carrier or diluent.
[0112] As regards these applications, the present method includes the administration to an animal, particularly a mammal, and more particularly a human, of a therapeutically effective amount of the compound effective in the treatment of a psychological disorder, such as
treatment resistant depression and other psychological disorders disclosed herein. The dose administered to an animal, particularly a human, in the context of the present invention should be sufficient to affect a therapeutic response in the animal over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors including the condition of the animal, the body weight of the animal, as well as the severity and stage of the disorder.
[0113] Thus, in one aspect, the invention relates to the manufacture of a medicament comprising combining PEH, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, with an antidepressant and a pharmaceutically acceptable carrier or diluent.
2. USE OF COMPOUNDS AND COMPOSITIONS
[0114] Also provided are the uses of the disclosed compounds and compositions. Thus, in one aspect, the invention relates to the uses of combination treatments for treating psychological disorders.
[0115] In a further aspect, the invention relates to the use of PEH and an antidepressant in the manufacture of a medicament for the treatment of a psychological disorder such as, for example, a severe anxiety disorder (e.g. , generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety) or obsessive-compulsive disorder (OCD).
[0116] In a further aspect, the use relates to a process for preparing a pharmaceutical composition comprising a therapeutically effective amount of PEH and an antidepressant, and a pharmaceutically acceptable carrier, for use as a medicament.
[0117] In a further aspect, the use relates to a process for preparing a pharmaceutical composition comprising a therapeutically effective amount of PEH and an antidepressant, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of PEH and an antidepressant.
[0118] In various aspects, the use relates to the treatment of a psychological disorder in a vertebrate animal. In a further aspect, the use relates to the treatment of a psychological disorder in a human subject.
[0119] In a further aspect, the use is the treatment of a psychological disorder, for example, a severe anxiety disorder (e.g. , generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression
with severe anxiety, and bipolar disorder with severe anxiety) or obsessive-compulsive disorder (OCD).
[0120] It is understood that the disclosed uses can be employed in connection with the disclosed compounds, methods, compositions, and kits. In a further aspect, the invention relates to the use of a disclosed compound or composition of a medicament for the treatment of a psychological disorder in a mammal.
[0121] In a further aspect, the invention relates to the use of a disclosed compound or composition in the manufacture of a medicament for the treatment of a psychological disorder such as, for example, a severe anxiety disorder (e.g., generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, treatment-resistant depression, depression with severe anxiety, and bipolar disorder with severe anxiety) or obsessive-compulsive disorder (OCD).
3. KITS
[0122] In one aspect, disclosed are kits comprising a compound having a structure:
and an antidepressant, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder. In one aspect, disclosed are kits comprising the compound and a 5HTIA receptor agonist, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder. [0123] In one aspect, disclosed are kits comprising PEH and an antidepressant, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder. In one aspect, disclosed are kits comprising PEH and a 5HTIA receptor agonist, and one or more of: (a) a device for delivering a medicament orally; and (b) instructions for treating a psychological disorder.
[0124] In some aspects, the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or buspirone.
[0125] Thus, in various aspects, the antidepressant is a SSRI. Examples of SSRIs include, but are not limited to, citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
[0126] In various aspects, the antidepressant is a SNRI. Examples of SNRIs include, but are not limited to, desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
[0127] In various aspects, the antidepressant is a TCA. Examples of TCAs include, but are not limited to, amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
[0128] In various aspects, the antidepressant is a 5HTIA receptor agonist. Examples of 5HTIA receptor agonists include, but are not limited to, buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone. In a further aspect, the 5HTIA receptor agonist is buspirone.
[0129] In some aspects, the psychological disorder is a severe anxiety disorder. Examples of severe anxiety disorders include, but are not limited to generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder, depression, depression with severe anxiety, and bipolar disorder with severe anxiety.
[0130] In some aspects, the psychological disorder is obsessive-compulsive disorder (OCD).
[0131] In some aspects, the psychological disorder is depression. In a further aspect, depression is treatment-resistant depression.
[0132] In some aspects, the compound and the antidepressant are co-packaged. In some aspects, the compound and the antidepressant are co-formulated.
[0133] In some aspects, PEH and the antidepressant are co-packaged. In some aspects, PEH and the antidepressant are co-formulated.
[0134] In some aspects, the compound and the antidepressant are administered sequentially. In some aspects, the compound and the antidepressant are administered simultaneously.
[0135] In some aspects, PEH and the antidepressant are administered sequentially. In some aspects, PEH and the antidepressant are administered simultaneously.
[0136] In some aspects, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises an effective amount of the compound and the antidepressant. In a further aspect, the kit further comprises a plurality of dosage forms, the plurality comprising one or more doses; wherein each dose comprises an effective amount of PEH and the antidepressant. In a still further aspect, the effective amount is a therapeutically effective amount. In yet a further aspect, the effective amount is a prophylactically effective amount.
[0137] In some aspects, each dose of the compound and the antidepressant are coformulated. In a still further aspect, each dose of the compound and the antidepressant are copackaged.
[0138] In some aspects, each dose of PEH and the antidepressant are co-formulated. In a still further aspect, each dose of PEH and the antidepressant are co-packaged.
[0139] In some aspects, each dose of the compound and the antidepressant are administered sequentially. In a still further aspect, each dose of the compound and the antidepressant are administered simultaneously.
[0140] In some aspects, each dose of PEH and the antidepressant are administered sequentially. In a still further aspect, each dose of PEH and the antidepressant are administered simultaneously.
[0141] In some aspects, the dosage forms are formulated for oral administration, inhalation, topical administration, and/or parenteral administration. In a still further aspect, the dosage form for the compound is formulated for oral administration and the dosage form for the antidepressant is formulated for parental administration. In yet a further aspect, the dosage form for the compound is formulated for parental administration and the dosage form for the antidepressant is formulated for oral administration. In an even further aspect, the dosage form for the compound is formulated for topical administration and the dosage form for the antidepressant is formulated for parental administration. In a still further aspect, the dosage form for the compound is formulated for parental administration and the dosage form for the antidepressant is formulated for topical administration. In yet a further aspect, the dosage form for the compound is formulated for oral administration and the dosage form for the antidepressant is formulated for inhalation. In an even further aspect, the dosage form for the compound is formulated for inhalation and the dosage form for the antidepressant is formulated for oral administration. In a still further aspect, the dosage form for the compound is formulated for topical administration and the dosage form for the antidepressant is formulated for inhalation. In a yet further aspect, the dosage form for the compound is formulated for inhalation and the dosage form for the antidepressant is formulated for topical administration.
[0142] In various aspects, the dosage form for PEH is formulated for oral administration and the dosage form for the antidepressant is formulated for parental administration. In yet a further aspect, the dosage form for PEH is formulated for parental administration and the dosage form for the antidepressant is formulated for oral administration. In an even further aspect, the dosage form for PEH is formulated for topical administration and the dosage form
for the antidepressant is formulated for parental administration. In a still further aspect, the dosage form for PEH is formulated for parental administration and the dosage form for the antidepressant is formulated for topical administration. In yet a further aspect, the dosage form for PEH is formulated for oral administration and the dosage form for the antidepressant is formulated for inhalation. In an even further aspect, the dosage form for PEH is formulated for inhalation and the dosage form for the antidepressant is formulated for oral administration. In a still further aspect, the dosage form for PEH is formulated for topical administration and the dosage form for the antidepressant is formulated for inhalation. In a yet further aspect, the dosage form for PEH is formulated for inhalation and the dosage form for the antidepressant is formulated for topical administration.
[0143] It is understood that the disclosed kits can be prepared from the disclosed compounds, products, and pharmaceutical compositions. It is also understood that the disclosed kits can be employed in connection with the disclosed methods of using.
4. SUBJECTS
[0001] In various aspects, the subject of the herein disclosed methods is a vertebrate, e.g., a mammal. Thus, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. A patient refers to a subject afflicted with a disease or disorder. The term “patient” includes human and veterinary subjects.
[0002] In some aspects of the disclosed methods, the subject has been diagnosed with a need for treatment prior to the administering step. In some aspects of the disclosed method, the subject has been diagnosed with a psychological disorder prior to the administering step. In some aspects of the disclosed methods, the subject has been identified with a need for treatment prior to the administering step. In one aspect, a subject can be treated prophylactically with a compound or composition disclosed herein, as discussed herein elsewhere. a. DOSAGE
[0003] Toxicity and therapeutic efficacy of the agents and pharmaceutical compositions described herein can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LDso (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The
dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50. Polypeptides or other compounds that exhibit large therapeutic indices are preferred.
[0004] Data obtained from cell culture assays and further animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity, and with little or no adverse effect on a human's ability to hear. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any agents used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (that is, the concentration of the test compound which achieves a half- maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Exemplary dosage amounts of a differentiation agent are at least from about 0.01 to 3000 mg per day, e.g, at least about 0.00001, 0.0001, 0.001, 0.01, 0.1, 1, 2, 5, 10, 25, 50, 100, 200, 500, 1000, 2000, or 3000 mg per kg per day, or more.
[0005] The formulations and routes of administration can be tailored to the disease or disorder being treated, and for the specific human being treated. For example, a subject can receive a dose of the agent once or twice or more daily for one week, one month, six months, one year, or more. The treatment can continue indefinitely, such as throughout the lifetime of the human. Treatment can be administered at regular or irregular intervals (once every other day or twice per week), and the dosage and timing of the administration can be adjusted throughout the course of the treatment. The dosage can remain constant over the course of the treatment regimen, or it can be decreased or increased over the course of the treatment.
[0006] In various aspects, the dosage facilitates an intended purpose for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation or allergic response. Although individual needs may vary, the determination of optimal ranges for effective amounts of formulations is within the skill of the art. Human doses can readily be extrapolated from animal studies (Katocs et al., (1990) Chapter 27 in Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA). In general, the dosage required to provide an effective amount of a formulation, which can be adjusted by one skilled in the art, will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient,
frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) (Nies et al., (1996) Chapter 3, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY). b. ROUTES OF ADMINISTRATION
[0007] Also provided are routes of administering the disclosed compounds and compositions. The compounds and compositions of the present invention can be administered by direct therapy using systemic administration and/or local administration. In various aspects, the route of administration can be determined by a patient's health care provider or clinician, for example following an evaluation of the patient. In various aspects, an individual patient's therapy may be customized, e.g, the type of agent used, the routes of administration, and the frequency of administration can be personalized. Alternatively, therapy may be performed using a standard course of treatment, e.g. , using pre-selected agents and pre-selected routes of administration and frequency of administration.
[0008] Systemic routes of administration can include, but are not limited to, parenteral routes of administration, e.g, intravenous injection, intramuscular injection, and intraperitoneal injection; enteral routes of administration e.g, administration by the oral route, lozenges, compressed tablets, pills, tablets, capsules, drops (e.g. , ear drops), syrups, suspensions and emulsions; rectal administration, e.g, a rectal suppository or enema; a vaginal suppository; a urethral suppository; transdermal routes of administration; and inhalation (e.g, nasal sprays). [0009] In various aspects, the modes of administration described above may be combined in any order.
[0010] The foregoing description illustrates and describes the disclosure. Additionally, the disclosure shows and describes only the preferred embodiments but, as mentioned above, it is to be understood that it is capable to use in various other combinations, modifications, and environments and is capable of changes or modifications within the scope of the invention concepts as expressed herein, commensurate with the above teachings and/or the skill or knowledge of the relevant art. The embodiments described herein above are further intended to explain best modes known by applicant and to enable others skilled in the art to utilize the disclosure in such, or other, embodiments and with the various modifications required by the particular applications or uses thereof. Accordingly, the description is not intended to limit the invention to the form disclosed herein. Also, it is intended to the appended claims be
construed to include alternative embodiments.
[0011] All publications and patent applications cited in this specification are herein incorporated by reference, and for any and all purposes, as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. In the event of an inconsistency between the present disclosure and any publications or patent application incorporated herein by reference, the present disclosure controls.
[0144] It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other aspects of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims
1. A method for treating a psychological disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of phenylethylidenehydrazine (PEH) or a pharmaceutically acceptable salt thereof, and an antidepressant.
3. The method of claim 2, wherein the counterion is selected from halogen, acetate, alginate, ascorbate, benzoate, carbonate, cinnamate, citrate, diphosphate, fumarate, gluconate, lactate, laurate, malate, maleate, mesylate, myristate, nitrate, palmitate, phosphate, propionate, sorbate, succinate, sulfate, tartrate, and a conjugate base of a phenolic acid.
4. The method of claim 1, wherein the pharmaceutically acceptable salt is a Lewis acidbase adduct.
6. The method of claim 5, wherein the Lewis acid is a non-Bronsted acid.
7. The method of claim 5, wherein the residue of a Lewis acid is -BF3 or -A1CL.
33
8. The method of claim 1, wherein the method comprises administering a pharmaceutical composition comprising an effective amount of PEH or the pharmaceutically acceptable salt thereof.
9. The method of claim 1, wherein the method comprises administering a single dose of PEH or the pharmaceutically acceptable salt thereof.
10. The method of claim 1, wherein the method comprises administering multiple doses of PEH or the pharmaceutically acceptable salt thereof.
11. The method of any one of claims 1 to 10, wherein a single administration of PEH or the pharmaceutically acceptable salt thereof is sufficient to alleviate symptoms of the psychological disorder for a period of at least 8 hours.
12. The method of any one of claims 1 to 7 and 9 to 11, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are administered sequentially.
13. The method of claim 12, wherein PEH or the pharmaceutically acceptable salt thereof is administered prior to administration of the antidepressant.
14. The method of claim 12, wherein PEH or the pharmaceutically acceptable salt thereof is administered subsequent to administration of the antidepressant.
15. The method of any one of claims 1 to 11, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressentant are administered simultaneously.
16. The method of any one of claims 1 to 15, wherein the subject is a mammal.
17. The method of claim 16, wherein the mammal is a human.
18. The method of any one of claims 1 to 17, wherein the subject has been diagnosed as having the psychological disorder prior to the administering step.
19. The method of any one of claims 1 to 17, wherein the subject has not been diagnosed as having a seizure disorder, a developmental disorder, a neurological disorder, a behavioral disorder, or addiction prior to the administering step.
20. The method of any one of claims 1 to 19, further comprising identifying a subject in need of treatment of a psychological disorder.
34
21. The method of any one of claims 1 to 20, wherein the effective amount is a therapeutically effective amount.
22. The method of claim 1, wherein the effective amount is a prophylactically effective amount.
23. The method of claim 1, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are together present in an effective amount.
24. The method of claim 1, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are each present in individually effective amounts.
25. The method of any one of claims 1 to 124, wherein PEH or the pharmaceutically acceptable salt thereof is formulated as an oral dosage form.
26. The method of any one of claims 1 to 24, wherein the antidepressant is formulated as an oral dosage form.
27. The method of claim 1, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are administered as a single dosage form.
28. The method of claim 27, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are orally administered as a single dosage form.
29. The method of any one of claims 1 to 28, wherein PEH or the pharmaceutically acceptable salt thereof is administered at a dose of from about 0.5 mg/kg/day to about 3 mg/kg/day.
30. The method of any one of claims 1 to 29, wherein the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or a 5HTIA receptor agonist.
31. The method of claim 30, wherein the SSRI is selected from citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vortioxetine.
32. The method of claim 30, wherein the SNRI is selected from desvenlafaxine, duloxetine, levomilnacipran, and venlafaxine.
33. The method of claim 30, wherein the TCA is selected from amitriptyline, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine.
34. The method of claim 30, wherein the 5HTIA receptor agonist is selected from buspirone, trazodone, nefazodone, vortioxetine, flibanserin, etappirone, lesopitron, alnespirone, repinotan, and gepirone.
35. The method of claim 30, wherein the 5HTIA receptor agonist is buspirone.
36. The method of any one of claims 1 to 35, wherein the psychological disorder is a severe anxiety disorder.
37. The method of claim 36, wherein the severe anxiety disorder is selected from generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, depression with severe anxiety, and bipolar disorder with severe anxiety.
38. The method of any one of claims 1 to 35, wherein the psychological disorder is treatment-resistant depression or obsessive-compulsive disorder (OCD).
39. The method of any one of claims 1 to 38, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
40. The method of claim 39, wherein the adequate antidepressant treatment comprises administration of a 5HTIA receptor agonist, bupropion, a monoamine oxidase inhibitor, a SNRI, a SSRI, a TCA, nefazodone, trazodone, pramipexole, mirtazapine, or vortioxetin.
41. The method of claim 39, wherein the adequate treatment comprises administration of an agent selected from the group consisting of a SSRI, a SNRI, a TCA, a MAOI, and a 5HTIA receptor agonist.
42. The method of claim 39, wherein the subject has not responded to at least two adequate antidepressant treatments prior to the administering step.
43. The method of claim 42, wherein the two adequate antidepressant treatments comprise treatments with agents from two different classes of antidepressants.
44. A method for treating treatment-resistant depression in a human subject in need thereof, the method comprising orally administering to the subject an effective amount of
PEH or a pharmaceutically acceptable salt thereof, and an antidepressant, wherein the subject has not responded to at least one adequate antidepressant treatment prior to the administering step.
45. The method of claim 44, wherein the adequate antidepressant treatment comprises administration of a 5HTIA receptor agonist, bupropion, a monoamine oxidase inhibitor, a SNRI, a SSRI, a TCA, nefazodone, trazodone, pramipexole, mirtazapine, or vortioxetin.
46. The method of claim 44 or claim 45, wherein the subject has not been diagnosed as having a seizure disorder, a developmental disorder, a neurological disorder, a behavioral disorder, or addiction prior to the administering step.
47. A pharmaceutical composition comprising PEH or a pharmaceutically acceptable salt thereof, an antidepressant, and a pharmaceutically acceptable carrier, wherein at least one of the compound and the antidepressant is present in a therapeutically effective amount, or wherein the compound and the antidepressant are together present in a therapeutically effective amount.
48. The pharmaceutical composition of claim 47, wherein the composition is formulated as a single oral dosage form.
49. The pharmaceutical composition of claim 47 or claim 48, wherein PEH or the pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.
50. The pharmaceutical composition of claim 47 or claim 48, wherein the antidepressant is present in a therapeutically effective amount.
51. The pharmaceutical composition of any one of claims 47 to 50, wherein PEH or the pharmaceutically acceptable salt thereof and the antidepressant are together present in a therapeutically effective amount.
52. A kit comprising PEH or a pharmaceutically acceptable salt thereof, and an antidepressant, and one or more of:
(a) a device for delivering a medicament orally; and
(b) instructions for treating a psychological disorder.
37
53. The kit of claim 52, wherein the antidepressant is a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), a tricyclic antidepressant (TCA), or a 5HTIA receptor agonist.
54. The kit of claim 52 or claim 53, wherein the device is a teaspoon, a tablespoon, a medicine cup, a calibrated medicine spoon, a calibrated oral medicine dropper, an oral dosing syringe, an injectable syringe, and a medicine bottle.
55. The kit of any one of claims 52 to 54, wherein the psychological disorder is a severe anxiety disorder is selected from generalized anxiety disorder (GAD), panic disorder, seasonal affective disorder (SAD), depression, depression with severe anxiety, and bipolar disorder with severe anxiety.
56. The kit of any one of claims 52 to 54, wherein the psychological disorder is treatmentresistant depression or obsessive-compulsive disorder (OCD).
38
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163143556P | 2021-01-29 | 2021-01-29 | |
US63/143,556 | 2021-01-29 | ||
US202163236061P | 2021-08-23 | 2021-08-23 | |
US63/236,061 | 2021-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022165382A1 true WO2022165382A1 (en) | 2022-08-04 |
Family
ID=82654959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/014629 WO2022165382A1 (en) | 2021-01-29 | 2022-01-31 | Phenylethylidenehydrazine combination therapies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022165382A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114453A1 (en) * | 2021-12-16 | 2023-06-22 | Neurawell Therapeutics | Phenylethylidenehydrazine dimers and methods of using same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060089335A1 (en) * | 2003-10-14 | 2006-04-27 | Guosong Liu | Compositions and methods for enhancing cognitive function and synaptic plasticity |
US20110009492A1 (en) * | 2009-07-10 | 2011-01-13 | The Governors Of The University Of Alberta | ß-PHENYLETHYLIDENEHYDRAZINE DERIVATIVES |
US8367657B2 (en) * | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
US20140057938A1 (en) * | 2010-12-01 | 2014-02-27 | Pfizer Inc. | KAT ll INHIBITORS |
US20190167632A1 (en) * | 2009-07-24 | 2019-06-06 | Wolfgang S. Mueller | Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
WO2020018779A1 (en) * | 2018-07-18 | 2020-01-23 | Ovid Therapeutics Inc. | Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction |
-
2022
- 2022-01-31 WO PCT/US2022/014629 patent/WO2022165382A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8367657B2 (en) * | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
US20060089335A1 (en) * | 2003-10-14 | 2006-04-27 | Guosong Liu | Compositions and methods for enhancing cognitive function and synaptic plasticity |
US20110009492A1 (en) * | 2009-07-10 | 2011-01-13 | The Governors Of The University Of Alberta | ß-PHENYLETHYLIDENEHYDRAZINE DERIVATIVES |
US20190167632A1 (en) * | 2009-07-24 | 2019-06-06 | Wolfgang S. Mueller | Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
US20140057938A1 (en) * | 2010-12-01 | 2014-02-27 | Pfizer Inc. | KAT ll INHIBITORS |
WO2020018779A1 (en) * | 2018-07-18 | 2020-01-23 | Ovid Therapeutics Inc. | Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction |
Non-Patent Citations (2)
Title |
---|
MATVEYCHUK ET AL.: "Elevation of rat brain tyrosine levels by phenelzine is mediated by its active metabolite B-phenylethylidenehydrazine", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY, vol. 53, 4 August 2014 (2014-08-04), pages 67 - 73, XP055676377, DOI: 10.1016/j.pnpbp.2014.02.011 * |
PARENT MARISE B., MASTER SANGEETA, KASHLUB SHAUNA, BAKER GLEN B.: "Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular γ-aminobutyric acid levels in the striatum", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 63, no. 1, 1 January 2002 (2002-01-01), US , pages 57 - 64, XP055960078, ISSN: 0006-2952, DOI: 10.1016/S0006-2952(01)00856-5 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023114453A1 (en) * | 2021-12-16 | 2023-06-22 | Neurawell Therapeutics | Phenylethylidenehydrazine dimers and methods of using same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BUNNEY JR et al. | Studies of alpha-methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania | |
US11458111B2 (en) | Ketogenic diet compatible fenfluramine formulation | |
US11839600B2 (en) | Neurodevelopmental disorder therapy | |
Ogata et al. | Selective serotonin reuptake inhibitors | |
US20240024340A1 (en) | Compositions and Methods For Treating Migraine | |
CN115192575A (en) | Methods of treating Lennox-Gastaut syndrome using fenfluramine | |
US20200323823A1 (en) | Methods for the treatment of depression | |
TW200936144A (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
EP4093296A1 (en) | Paraxanthine-based bioactive composition and method of use thereof | |
US20240050454A1 (en) | Compositions and Methods For Treating Neurological Conditions | |
Raskin et al. | Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder | |
US10058552B2 (en) | Combination of creatine, an omega-3 fatty acid, and citicoline | |
WO2022165382A1 (en) | Phenylethylidenehydrazine combination therapies | |
Crowell-Davis et al. | Tricyclic antidepressants | |
Zhan et al. | Serotonin Syndrome Induced by a Single Dose of Venlafaxine and Magnesium Valproate | |
US20230086660A1 (en) | Oral formulations of metronidazole and methods of treating an infection using same | |
US11541092B2 (en) | Composition for increasing sexual desire or pleasure | |
CN108078984A (en) | The composition and its application of serotonin and norepinephrine reuptake inhibitors and cannabidiol | |
RU2822657C2 (en) | Esketamine for treating depression | |
WO2023215338A1 (en) | Compositions and methods for treating cluster headache | |
WO2023215342A1 (en) | Compositions and methods for treating trigeminal neuralgia | |
Gavrilova et al. | Application of Iversan drug for gasterophilosis treatment in horses | |
US20140228402A1 (en) | Combinations Comprising a S1P receptor modulator | |
WO2023215344A2 (en) | Compositions and methods for treating cluster-tic syndrome | |
CA3175141A1 (en) | Composition for preventing deterioration in cognitive function and/or improving cognitive function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22746840 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.11.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22746840 Country of ref document: EP Kind code of ref document: A1 |